Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 43 Carcinoma, Hepatocellular 19 Rectal Neoplasms 10 Colonic Neoplasms 10 Neoplasm Metastasis 9 Gastrointestinal Stromal Tumors 8 Sarcoma 5 Ovarian Neoplasms 5 Cholangiocarcinoma 5 Melanoma 4 Pancreatic Neoplasms 3 Osteosarcoma 3 Liver Neoplasms 3 Glioblastoma 3 Stomach Neoplasms 2 Neoplasms 2 Lung Neoplasms 2 Gallbladder Neoplasms 2 Fatigue 2 Esophageal Neoplasms 2 Colorectal Cancer Metastatic 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Bile Duct Neoplasms 2 Adenocarcinoma 2 Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1 Thyroid Neoplasms 1 Thymoma 1 Squamous Cell Carcinoma of Head and Neck 1 Somatostatinoma 1

Interventions

tislelizumab 1 regorafenib 1 Trace amine-associated receptor 1 1 Thymalfasin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × MCRC × regorafenib × Clear all

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting

MCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡